Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that effectively suppresses appetite in most patients
A study published in Diabetes, Obesity and Metabolism (Frias et al., 2021) from an early phase 2 comparison found that tirzepatide produced dose-dependent weight loss that exceeded semaglutide 1 mg across all dose levels tested, confirming the advantage of the dual mechanism
Severe vitamin C deficiency, called scurvy, is a potentially fatal disease
Production of recombinant protein therapeutics in cultivated mammalian cells
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
